Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07116278 · ClinicalTrials.gov registry record · NA

TMS-EEG Biomarkers for Chronic Pain

A NA study of Chronic Pain, sponsored by University of California, San Francisco.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT07116278: Active NA study of Chronic Pain, sponsored by University of California, San Francisco.

NCT07116278 is a NA study of Chronic Pain that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 100 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07116278, a NA study of Chronic Pain, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

In this study the investigators aim to assess the correlates of neurophysiological measures (measurement of brain magnetically evoked response) using DELPHI system. The DELPHI system device is a computerized, electromechanical medical device that produces and delivers non-invasive Transcranial Magnetic Stimulation (TMS) fields to induce electrical currents directed at regions of the cerebral cortex and records the resultant Electroencephalogram (EEG) brain electrophysiological response. DELPHI analyzes the TMS Evoked Potential (TEP) and produces quantitative output measures. Objectives include: * To use TMS-evoked EEG measures of brain function in patients with chronic pain using the QuantalX DELPHI system to predict patient specific pain diagnoses using machine learning classification methods. * To evaluate longitudinal associations between TMS-evoked EEG measures and ratings of chronic pain. * To monitor associations between TMS-evoked EEG biomarkers and therapy success for three different classes of medications.

Primary Outcome

The QuantalX DELPHI (TMS-EEG) system will be used to generate N45 potential amplitudes from the primary motor cortex. The DELPHI System is used for acquisition of physiological signals of Electroencephalography (EEG) from the scalp in response to magnetic stimulation. It consists of a DELPHI amplifier, a computer (workstation), a patient EEG cap, a transcranial magnetic stimulation (TMS) device and "Figure 8" stimulation coil. To limit the effect of medications on EEG results, participants will

Conditions Studied

Interventions

  • DEVICE QuantalX DELPHI-MD (TMS-EEG)

Study Locations (1)

California

  • UCSF - San Francisco

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-11-18
Est. Completion 2026-06
Phase NA

What the registry record for NCT07116278 still lists

NCT07116278 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which QuantalX DELPHI-MD (TMS-EEG) is the first listed.

NCT07116278 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07116278 about?

NCT07116278 is a clinical study titled "TMS-EEG Biomarkers for Chronic Pain". In this study the investigators aim to assess the correlates of neurophysiological measures (measurement of brain magnetically evoked response) using DELPHI system. The DELPHI system device is a computerized, electromechanical medical device that produces and delivers non-invasive Transcranial Magne...

What is the current status of trial NCT07116278?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-11-18. Estimated completion is 2026-06.

What conditions does trial NCT07116278 study?

This clinical trial studies the following conditions: Chronic Pain.

What interventions are being tested in trial NCT07116278?

The interventions under investigation include: QuantalX DELPHI-MD (TMS-EEG) (DEVICE).

Who is sponsoring clinical trial NCT07116278?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07116278 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07116278's enrollment target sits among peer trials

100 132nd of 301 higher than 164 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07116278, the US trial registry maintained by the National Library of Medicine. NCT07116278 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.